

Overview: Barriers to Competition

- Barriers Are: Good and Bad, Big and Small
- Some Are Good
- Many Are Bad
- Consequences of Barriers
- Policy Implications
- Conclusion

Not All Barriers Are Created Equal

- Broadly speaking, barriers to biosimilar entry have mixed effects:
 - Some are appropriate for protecting producers and consumers
 - Others thwart healthy competition and a robust biosimilars market
- But barriers to biosimilar utilization are uniformly undesirable



Good Barriers

- Barriers are good if they create appropriate monopoly periods for reference products
-

Bad Barriers

- Barriers that impede biosimilar utilization hurt competition and reduce consumer welfare
 - Myopic contracting practices by payers
 - “Rebate traps”
 - Frivolous late-stage patents
 - Inadequate physician and patient education

Consequences of Bad Barriers

- Undue barriers to biosimilar entry and utilization have many consequences
 - Excessive monopoly rents
 - Higher patient cost
 - Less biosimilar discounting
 - Fewer biosimilar competitors

Uncertainty Is a Unique Barrier

- A final barrier: the uncertainty associated with the viability of the biosimilars market
 - Uncertainty of reference product price
 -
-

Policy Implications

- Policies to combat barriers to biosimilars should heed three principles:
 - Predictability. Biosimilar manufacturers should be reasonably able to anticipate the cost (including duration) of barriers to entry
 - Minimal market interference. Minimize (to the extent possible) costs related to approval
 - Maximum market receptivity. Educate physicians, payers, and patients



Conclusion

- Many of the barriers that impeded biosimilar entry after enactment of BPCIA have been mitigated as FDA and the courts have resolved legal and regulatory uncertainties
- Inefficient and costly barriers remain, and policymakers, manufacturers, and payers all have a role to play in reducing those barriers